Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL635071 | 0.91 | KDM4E (0.52) | KDM4ELMNAL3MBTL1ALDH1A1HPGD | |
| SCHEMBL4105342 | 0.87 | KDM4E (0.41) | KDM4ELMNARECQLL3MBTL1ALDH1A1 | |
| SCHEMBL21798647 | 0.85 | MEN1 (0.43) | KDM4ELMNAMEN1KMT2ARECQL | |
| SCHEMBL634242 | 0.83 | LPAR5 (0.49) | KDM4EALDH1A1HPGDTP53LPAR5 | |
| SCHEMBL21798648 | 0.83 | KMT2A (0.41) | KDM4ELMNAMEN1KMT2ARECQL | |
| SCHEMBL21798683 | 0.83 | AHR (0.41) | KDM4ELMNAMEN1KMT2ARECQL | |
| SCHEMBL4105365 | 0.83 | RAD52 (0.44) | KDM4EMEN1KMT2ARECQLL3MBTL1 | |
| SCHEMBL636006 | 0.82 | KDM4E (0.37) | KDM4ELMNAL3MBTL1ALDH1A1HPGD | |
| SCHEMBL634087 | 0.80 | KDM4E (0.41) | KDM4ELMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL30122318 | 0.80 | KDM4E (0.41) | KDM4ELMNAMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | BAGULEY BRUCE CHARLES | 2009-06-18 | — | — | US | claimed |
| US-11046687-B2 | Polycyclic amide compound, preparation process and use thereof | HEBEI GRANDIOS PHARMA CO., LTD. | 2021-06-29 | — | — | US | disclosed |
| US-20200079771-A1 | Novel Polycyclic Amide Compound, Preparation Process And Use Thereof | HEBEI GRANDIOS PHARMA CO., LTD. (CN) | 2020-03-12 | — | — | US | disclosed |
| EP-1507778-B1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | UNIV TROBE (AU) | 2012-02-22 | — | — | EP | disclosed |
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | BAGULEY BRUCE CHARLES | 2009-06-18 | — | — | US | disclosed |
| US-7504507-B2 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-03-17 | — | — | US | disclosed |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | MKI67, MCL1, CCNI | KDM4E 744/4885LMNA 609/4885MEN1 1279/4885 |
| US-20200079771-A1 | Novel Polycyclic Amide Compound, Preparation Process And Use Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0, UACA | KDM4E 3677/4885LMNA 2279/4885MEN1 936/4885 |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | MKI67, MCL1, CCNI | KDM4E 880/4885LMNA 537/4885MEN1 1089/4885 |
| US-11046687-B2 | Polycyclic amide compound, preparation process and use thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UACA, H1-0 | KDM4E 3723/4885LMNA 2148/4885MEN1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.